Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 11/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.38 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | UBE2M | P61081 | 1/20 | 0.37 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206310 | 0.80 | OPRM1 (0.43) | OPRM1OPRD1OPRK1ALDH1A1MEN1 | |
| SCHEMBL206538 | 0.77 | SMN1; SMN2 (0.59) | OPRM1OPRD1OPRK1ALDH1A1MEN1 | |
| SCHEMBL2199235 | 0.77 | TACR1 (0.41) | TACR1ALDH1A1HSD17B10HPGD | |
| SCHEMBL206215 | 0.73 | SMN1; SMN2 (0.47) | OPRM1OPRD1OPRK1ALDH1A1MEN1 | |
| SCHEMBL6952343 | 0.72 | L3MBTL1 (0.49) | TACR1SMN1; SMN2 | |
| SCHEMBL206381 | 0.72 | NPSR1 (0.54) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL206989 | 0.71 | TACR1 (0.46) | TACR1MEN1KMT2A | |
| SCHEMBL206203 | 0.71 | KDM4E (0.46) | ALDH1A1MEN1KMT2AHSD17B10HPGD | |
| SCHEMBL12482320 | 0.70 | SMN1; SMN2 (0.48) | OPRK1TACR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL580852 | 0.70 | PSEN1 (0.49) | TACR1ALDH1A1SMN1; SMN2HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | OPRM1 2752/4885OPRD1 2783/4885OPRK1 1364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.